By Adriano Marchese
Regeneron Pharmaceuticals signed a new manufacturing-and-supply agreement with Fujifilm Diosynth Biotechnologies to double its large-scale manufacturing in the U.S.
Regeneron's new investment with Fujifilm, whose total value is estimated to exceed $3 billion, will expand the Tarrytown, N.Y., biotechnology company's manufacturing capabilities at Fujifilm's Holly Springs, N.C., campus, nearly doubling its large-scale capacity in the U.S.
This expansion will increase the production of bulk drug substances and Regeneron's commercial biologic medicines, the company said Tuesday.
Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm, which develops manufacturing for biologics, vaccines and advanced therapies, will provide Regeneron with access to its new state-of-the-art biopharmaceutical facility over a 10-year period.
The investment comes at the same time as Regeneron's initiatives in New York State, including a roughly $3.6 billion expansion of its Tarrytown campus that will bolster research, preclinical manufacturing and support facilities.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 22, 2025 06:54 ET (10:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。